Effects of GM1 injection combined with hyperbaric oxygen on sudden deafness and its related mechanism
10.3760/cma.j.cn311847-20191220-00410
- VernacularTitle:GM1注射液联合高压氧治疗突发性耳聋的疗效及机制分析
- Author:
Haimin SUN
1
;
Jing ZHANG
;
Ningning WANG
;
Zhu WU
Author Information
1. 266000 山东省青岛 青岛市市立医院耳鼻咽喉头颈外科
- Publication Type:Journal Article
- Keywords:
Monosialoganglioside sodium;
Hyperbaric oxygen;
Sudden deafness;
Curative effect;
Mechanism
- From:
Chinese journal of nautical medicine and hyperbaric medicine
2020;27(6):713-717
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the therapeutic effect of monosialoganglioside sodium (GM1) injection combined with hyperbaric oxygen(HBO) in the treatment of sudden deafness and to analyze its related mechanism.Methods:A total of 200 patients with sudden deafness admitted into the Department of Otorhinolaryngology, Head and Neck Surgery of Qingdao Municipal Hospital from May 2016 to July 2018 were selected and randomly divided into four groups: conventional group (conventional medical treatment), GM1 group (conventional medical treatment+ GM1 injection), HBO group (conventional medical treatment+ HBO treatment), and GM1+ HBO group (conventional medical treatment+ GM1 injection+ HBO), each consisting of 50 patients. The clinical effects of the four groups after treatment were compared, the changes of the average air-conduction hearing threshold, symptom score, and the levels of whole blood viscosity, plasma viscosity, fibrinogen and vascular endothelial growth factor (VEGF), intercellular adhesion factor-1 (ICAM-1), soluble vascular cell adhesion molecule-1 (sVCAM-1) before and after treatment were recorded and compared. The incidences of adverse reactions during the treatment in each group were observed.Results:The total effective rate of the GM1+ HBO group was 98.00%, which was significantly higher than those of the other three groups (78.00%, 82.00%, and 86.00%) ( P<0.05); in each group, after treatment, the average air-conduction hearing threshold of the patients was significantly lower than that before treatment ( P<0.05), and the symptom score of the patient was significantly lower than that before treatment ( P<0.05); after treatment, the average air-conduction hearing threshold and symptom score of the patients in the GM1+ HBO group were significantly lower than those in the other three groups ( P<0.05); after treatment, the levels of whole blood viscosity, plasma viscosity, and fibrinogen in each group were significantly lower than those before treatment, especially, those in the GM1+ HBO group were significantly lower than those in the other three groups ( P<0.05); after treatment, the level of VEGF in each group was significantly higher than that before treatment, especially, that in the GM1+ HBO group was significantly higher than those in the other three groups ( P<0.05); the levels of ICAM-1 and sVCAM-1 were lower than those before treatment, and those in the GM1 + HBO group were significantly lower than those in the other three groups ( P<0.05). The total incidence of adverse reactions in the GM1+ HBO group was slightly higher than those in the other three groups, but the differences were not statistically significant ( P>0.05). Conclusion:GM1 injection combined with HBO is effective in the treatment of sudden deafness, which can significantly improve the hearing of patients. It may be achieved by repairing the damaged endothelium through improving the coagulation and vascular endothelial function of patients. The therapy is worthy of clinical application.
